Identification of cystic fibrosis transmembrane regulator (CFTR) mutations in Chilean patients with cystic fibrosis

被引:0
|
作者
Repetto, G
Poggi, H
Harris, P
Navarro, H
Sánchez, I
Guiraldes, E
Pérez, MA
Boza, ML
Hunter, B
Wevar, ME
Mediavilla, M
Foradori, A
机构
[1] Pontificia Univ Catolica Chile, Fac Med, Dept Pediat, Santiago, Chile
[2] Pontificia Univ Catolica Chile, Fac Med, Lab Desarrollo & Biol Mol, Santiago, Chile
[3] Hosp San Borja Arriaran, Hosp Exequiel Gonzales Gortes, Serv Pediat, Valdivia, Chile
[4] Hosp Base Valdivia, Valdivia, Chile
[5] Hosp Ninos Luis Calvo Mackenna, Unidades Neumonol & Gastroenterol, Santiago, Chile
[6] Pontificia Univ Catolica Chile, Fac Med, EEUU & UDA Labs Clin, Santiago, Chile
关键词
cystic fibrosis; cystic fibrosis transmembrane conductance regulator; counseling; genetics; medical;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cystic fibrosis (CF) is all autosomal recessive disease caused by mutations in the CFTR gene that codes for a chloride channel located in the apical surface of epithelial cells. The main role of this protein is the regulation of chloride transport, and secondarily, of sodium and water to the extracellular space. More than 900 gene mutations have been described, and their relative frequency in different populations depends on their ethnic origin. Aim: To report the findings of Chilean patients with cystic fibrosis, in whom the presence of 20 common mutations was analyzed. Patients and methods: Fifty seven patients with established diagnosis or suspicion of CF, were studied. The simultaneous identification of 20 mutations and the normal Delta F508 allele was done using polymerase chain reactions with a commercial assay. Results: Eight mutations were found. Fifty patients fulfilled diagnostic criteria proposed by the Consensus Panel of the CF Foundation and 66% of alleles were identified in this group. Delta F508 mutation was found in 45%. We did not identify mutations in any of the remaining 7 patients. Conclusions: Our results suggest that the majority of undetected mutations are associated with atypical phenotypes or that some patients in this series could have other diseases. We recommend to include mutation analysis in the evaluation of Chilean patients with CF. It is useful to establish prognosis and genetic counselling (Rev Med Chile 2001; 129: 841-7).
引用
收藏
页码:841 / 847
页数:7
相关论文
共 50 条
  • [21] Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine
    Siryani, Issa
    Jama, Mohamed
    Rumman, Nisreen
    Marzouqa, Hiyam
    Kannan, Moein
    Lyon, Elaine
    Hindiyeh, Musa
    PLOS ONE, 2015, 10 (07):
  • [22] Effects of triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy on glucose metabolism in cystic fibrosis patients
    Yesquen, Pamela
    Campos, Ariadna
    Mogas, Eduard
    Yeste, Diego
    Gartnet, Silvia
    Clemente, Maria
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 201 - 201
  • [23] Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Allelic Variants Relate to Shifts in Faecal Microbiota of Cystic Fibrosis Patients
    Schippa, Serena
    Iebba, Valerio
    Santangelo, Floriana
    Gagliardi, Antonella
    De Biase, Riccardo Valerio
    Stamato, Antonella
    Bertasi, Serenella
    Lucarelli, Marco
    Conte, Maria Pia
    Quattrucci, Serena
    PLOS ONE, 2013, 8 (04):
  • [24] Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage
    Zhang, Shuzhong
    Shrestha, Chandra L.
    Kopp, Benjamin T.
    SCIENTIFIC REPORTS, 2018, 8
  • [25] The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
    Meng, Xin
    Clews, Jack
    Kargas, Vasileios
    Wang, Xiaomeng
    Ford, Robert C.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2017, 74 (01) : 23 - 38
  • [26] The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
    Xin Meng
    Jack Clews
    Vasileios Kargas
    Xiaomeng Wang
    Robert C. Ford
    Cellular and Molecular Life Sciences, 2017, 74 : 23 - 38
  • [27] Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators
    Eldredge, Jessica A.
    Oliver, Mark R.
    Ooi, Chee Y.
    PAEDIATRIC RESPIRATORY REVIEWS, 2024, 50 : 54 - 61
  • [28] Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR)
    Rosenberg, MF
    Kamis, AB
    Aleksandrov, LA
    Ford, RC
    Riordan, JR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (37) : 39051 - 39057
  • [29] Regulation of neurosecretion by the cystic fibrosis transmembrane conductance regulator (CFTR).
    Weyler, RT
    Altschuler, SM
    Mulberg, AE
    JOURNAL OF INVESTIGATIVE MEDICINE, 1998, 46 (03) : 207A - 207A
  • [30] Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutations and Risk for Pancreatic Adenocarcinoma
    McWilliams, Robert R.
    Petersen, Gloria M.
    Rabe, Kari G.
    Holtegaard, Leonard M.
    Lynch, Pamela J.
    Bishop, Michele D.
    Highsmith, W. Edward, Jr.
    CANCER, 2010, 116 (01) : 203 - 209